Johnson & Johnson Prevails in Talc Lawsuit, Launches New Medical Platform
Money

Johnson & Johnson Prevails in Talc Lawsuit, Launches New Medical Platform

authorBy Bola Sokunbi
DateJun 28, 2026
Read Time2 min

Johnson & Johnson has recently navigated a significant legal challenge while simultaneously introducing a pioneering medical device to the European market. A Los Angeles jury found the company not liable in a lawsuit concerning its talc products and alleged links to ovarian cancer. This legal victory comes as the firm faces numerous similar claims. Parallel to these legal developments, Johnson & Johnson has advanced its medical technology portfolio with the commercial debut of its Dual Energy THERMOCOOL SMARTTOUCH SF Platform in Europe, underscoring its continuous commitment to innovation in healthcare.

Johnson & Johnson Secures Legal Win Amidst Ongoing Talc Litigation, Unveils Advanced Medical Technology

In a notable legal development on June 6, a Los Angeles jury sided with Johnson & Johnson, absolving the company of claims that its talc products contributed to ovarian cancer in three women. This verdict comes amidst a backdrop of over 67,000 similar lawsuits targeting the healthcare behemoth. The company had previously ceased selling talc-based baby powder in the U.S. in 2020, transitioning to a cornstarch alternative. Just nine days later, on June 15, Johnson & Johnson announced the commercial launch of its Dual Energy THERMOCOOL SMARTTOUCH SF Platform across Europe. This advanced platform is designed to deliver both radiofrequency and pulsed-field energy through a single catheter, offering physicians enhanced capabilities to customize treatments for individual patient needs, as highlighted by Ricardo Martin, President of Johnson & Johnson. Early SmartfIRE data indicates an impressive 86.9% effectiveness rate over a 12-month period for this new technology.

This dual narrative of legal defense and medical innovation illustrates Johnson & Johnson's multifaceted approach to its business operations. The successful defense against the talc-related lawsuit, while significant, remains part of a larger ongoing legal battle. Concurrently, the introduction of the Dual Energy THERMOCOOL SMARTTOUCH SF Platform underscores the company's relentless pursuit of breakthroughs in healthcare. From a journalistic perspective, these events highlight the dynamic and often challenging environment in which large corporations operate, balancing legal responsibilities with the imperative to innovate and provide cutting-edge medical solutions. It prompts reflection on the evolving landscape of product liability and the continuous drive for technological advancement in the healthcare industry, ultimately influencing patient care and public trust.

More Articles
Money
CoreWeave: AI Infrastructure Investment and Growth Potential
CoreWeave, an AI infrastructure provider backed by Nvidia, is demonstrating significant growth potential. The company is benefiting from the increasing demand for AI data centers from major tech giants like Meta Platforms and Microsoft, as well as AI-focused firms such as OpenAI and Anthropic. With a massive revenue backlog and ambitious expansion plans, CoreWeave aims to capitalize on the rapidly expanding AI market.
By JL CollinsJun 28, 2026
Money
Chevron's CFO Explains Persistent High Gasoline Prices Amidst Oil Market Fluctuations
Despite a drop in crude oil prices, gasoline costs at the pump remain stubbornly high, leading to public and political scrutiny. Chevron CFO Eimear Bonner attributes this to a lag effect, stating that while Middle East oil flows are normalizing, it will take time for these changes to translate into lower consumer prices. The company plans to boost production, but market dynamics, refining processes, and regional factors all contribute to the slow adjustment of fuel costs.
By Ramit SethiJun 28, 2026
Money
Supreme Court Declines CareDx Appeal in Natera False Advertising Case
The U.S. Supreme Court has rejected CareDx's appeal in a false advertising dispute with Natera, Inc. (NTRA). This decision upholds lower court rulings that denied CareDx damages, despite confirming false advertising by Natera regarding its kidney transplant tests. The case centered on claims comparing Natera's Prospera test with CareDx's AlloSure test.
By Dave RamseyJun 28, 2026
Money
DexCom Expands Glucose Biosensor Access for All Ages
DexCom, Inc. (NASDAQ:DXCM) announced FDA clearance for its Stelo Glucose Biosensor, extending its use to children aged 2 and older who do not rely on insulin. This marks a significant step towards universal glucose biosensing, aiming to provide accessible and personalized care. The updated Stelo app, offering insights into glucose levels linked to lifestyle factors, will launch in the U.S. in July, with international expansion planned for late 2027.
By Scott PapeJun 28, 2026
Money
Veeva Systems' Strategic Acquisition and AI-Powered MLR Platform Launch
Veeva Systems Inc. (VEEV) has announced the acquisition of Copli and the simultaneous launch of Veeva Falcon MLR, an advanced AI-powered content review platform. This new solution is designed to automate the medical, legal, and regulatory (MLR) content review process, promising to significantly reduce manual workload and expedite information delivery to healthcare professionals and patients.
By Bola SokunbiJun 28, 2026